U.S. biopharmaceutical company Cabaletta Bio Inc. has bagged another $50 million in funding from its backers.

Cabaletta will use the new capital to finance clinical trials and add manufacturing capabilities for gene therapies it is advancing with the University of Pennsylvania, specifically to fight autoimmune diseases.

New backers in the round included Deerfield Management, Tavistock Group’s Boxer Capital, Redmile Group and Cormorant Capital with participation from Adage Capital Management, 5AM Ventures among others.

In addition, Cabaletta will use the funds to prepare its Investigational New Drug application to the U.S. Food and Drug Administration.